Natco Pharma gets USFDA nod for Vizag Formulation Facility

Written by Ruchika Sharma Published On 2020-04-29T12:58:28+05:30 | Updated On 29 April 2020 12:58 PM IST

Natco Pharma gets USFDA nod for Vizag Formulation Facility

Hyderabad: Natco Pharma Limited has announced the final approval of its 1st supplemental abbreviated new drug application (sANDA) product from the U.S. Food and Drug Administration (USFDA) filed from its new drug formulations facility in JNPC SEZ, Ramky Pharma City, Visakhapatnam (Vizag), Andhra Pradesh, India.

The sANDA, submitted as "Prior Approval Supplement," provides for NATCO' s Vizag facility as an alternate site for the manufacture of the approved drug product for the US market.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

natco-pharmausfda

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751